Table 1.

VERTIS phase 3 studies included in the analysis

VERTIS study name	MONO [24, 26]	MET [23, 27]	SITA2 [18]	SU [20, 28]	RENAL [19]	SITA [21]	FACTORIAL [22]
Clinicaltrials.gov identifier	NCT01958671	NCT02033889	NCT02036515	NCT01999218	NCT01986855	NCT02226003	NCT02099110
Number of patients randomized	N = 461	N = 621	N = 464	N = 1326	N = 468	N = 291	N = 1233
HbA1c inclusion criterion	7.0–10.5%	7.0–10.5%	7.0–10.5%	7.0–9.0%	7.0–10.5%	8.0–10.5%	7.5–11.0%
Background therapy	Diet and exercise	Metformin	Metformin and sitagliptin	Metformin	Diet/exercise with or without AHA	Diet and exercise	Metformin
Ertugliflozin treatment groups	Ertugliflozin 5 mg Ertugliflozin 15 mg	Ertugliflozin 5 mg Ertugliflozin 15 mg	Ertugliflozin 5 mg Ertugliflozin 15 mg	Ertugliflozin 5 mg Ertugliflozin 15 mg	Ertugliflozin 5 mg Ertugliflozin 15 mg	Ertugliflozin 5 mg + sitagliptin 100 mg Ertugliflozin 15 mg + sitagliptin 100 mg	Ertugliflozin 5 mg, Ertugliflozin 15 mg, each with and without sitagliptin 100 mg
Comparator	Placebo	Placebo	Placebo	Glimepiride	Placebo	Placebo	Sitagliptin
Duration	26 weeks + 26-week extension	26 weeks + 78-week extension	26 weeks + 26-week extension	52 weeks + 52-week extension	26 weeks + 26-week extension	26 weeks	26 weeks + 26-week extension

Table was adapted from Fig. 1 in Liu et al. [29]

AHA Antihyperglycemic agent, HbA1c glycated hemoglobin